New blood thinner for liver cirrhosis patients with variceal bleeding and portal vein clot
Treatments studied
Part of Blood & lymphatic, Digestive system clinical trials.
This trial tests a new oral blood thinner to prevent another bleeding episode in people with liver cirrhosis who have already had variceal bleeding and also have a clot in the portal vein. The goal is to see if it can safely reduce the risk of rebleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cirrhosis and have had at least one episode of bleeding from swollen veins in your esophagus or stomach (variceal bleeding).
- You have a blood clot in the portal vein (the main vein to the liver), and your D-dimer level is higher than 0.8 mg/L.
- An endoscopy (a tube with a camera) shows that your varices are at high risk of bleeding, and you are scheduled to have endoscopic treatment to prevent rebleeding.
- You have not taken any other blood thinners (like warfarin, aspirin, or low-molecular-weight heparin) before.
- You do not have liver cancer or other cancers, and you have not had TIPS, a liver transplant, or spleen removal.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a pill (dabigatran) or a daily injection (enoxaparin) is better at preventing new blood clots in the liver vein for people with cirrhosis. Both are blood thinners, and the study wants to see which one is safer and more effective.
This study tests whether a blood thinner called apixaban can safely prevent dangerous bleeding in people with cirrhosis (liver scarring) who have portal hypertension (high blood pressure in veins leading to the liver). The goal is to see if it reduces bleeding risk without causing excessive bleeding.
This study tests whether blood thinners (anticoagulants) are safe and effective for people with cirrhosis and a blood clot in the portal vein. It may also include people with liver cancer (HCC).
This early study tests whether the blood thinner pills rivaroxaban and apixaban can be used safely in people with liver cirrhosis that is not too severe. It may help doctors understand the safest way to prevent or treat blood clots in this group.
This trial compares two medicines to prevent blood clots after heart valve surgery. If you've had a tissue valve replaced or repaired, this study will see if a newer blood thinner (rivaroxaban) is safer and works better than the standard treatment.
This study tests a low-dose blood thinner called rivaroxaban, given for 90 days after a recent ischemic stroke, to see if it reduces the risk of another stroke or heart problems. It may be an option for people who are already receiving standard stroke care and are not on full-dose blood thinners.
Hear when a new Portal Vein Thrombosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.